DEC 01, 2021 7:00 AM PST

Using multiplex immunofluorescence to predict clinical outcomes in solid tumor cancer

Sponsored by: Akoya Biosciences
C.E. Credits: P.A.C.E. CE Florida CE
Speaker

Abstract
Date: December 01, 2021
Time: 7:00am (PST),  10:00am (EST)
 
In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-PD1 and/or anti-PDL1 therapies, each single or in combination with innovative drugs. While the tumoral PDL1 expression and MSI-high status are the sole approved biomarkers in Europe, they nevertheless remain imperfect tools sometimes failing in predicting treatment sensitivity. In a recent collaborative work supervised by Pr A. Italiano and published in Nature Cancer, we highlighted that the presence of mature tertiary lymphoid structures (mTLS) – a structure of prominent B cell follicles and follicular dendritic cells adjoined to a CD4/CD8 T cell-containing zone - is a new predictive biomarker of response for immune checkpoint blockers. In this webinar, we will describe how, on large series of tumor samples from patient cohorts, mTLS were captured through the automated application of a multiplexed immunofluorescence panel consisting of CD4, CD8, CD20, CD21, and CD23 markers, and multispectral image acquisition and analysis. Through spatial assessment of key phenotypes within the tumor microenvironment, it was possible to demonstrate that the presence of mature TLSs was associated with improved clinical benefit, paving the way for using spatial phenotyping to select cancer patients who are more likely to benefit from immune checkpoint blockade.
 
Learning Objectives
  • Discover how multiplex immunofluorescence can be applied to a clinical study to better apprehend response outcomes
  • Learn how to apply an automated multiplexing modality to a large cohort of samples with higher throughput
  • Learn how tertiary lymphoid structures could predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression
 
 
Webinars will be available for unlimited on-demand viewing after live event.
 
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.

Show Resources
You May Also Like
FEB 15, 2023 7:00 AM PST
FEB 15, 2023 7:00 AM PST
Date: February 15, 2023 Time: 7:00am (PST), 10:00pm (EST), 4:00pm (CET) While not all microscopy samples can fluoresce, all can scatter light, and this scattered light can be imaged. This ha...
NOV 16, 2022 7:00 PM PST
C.E. CREDITS
NOV 16, 2022 7:00 PM PST
Date: November 16, 2022 Time: 2:00pm (AEST) Date: November 17, 2022 7:00pm (PST), 10:00pm (EST), 4:00am (CET) The growth in FDA-approved cell and gene therapy products for the treatment of d...
AUG 24, 2022 7:00 AM PDT
AUG 24, 2022 7:00 AM PDT
Date: August 24, 2022 Time: 7:00am (PDT), 10:00pm (EDT), 4:00pm (CEST) Light field microscopy was first introduced in 2006, and allows users to capture the 4D light field within the microsco...
OCT 13, 2022 9:00 AM +08
OCT 13, 2022 9:00 AM +08
First Broadcast: Date: October 12, 2022 Time: 8:00am PDT, 11:00am EDT Second Broadcast: Date: October 12, 2022 Time: 9:00am SGT The new Embedded CryoSPARC Live, now fully integrated with t...
AUG 10, 2022 10:00 AM PDT
AUG 10, 2022 10:00 AM PDT
Date: August 10, 2022 Time: 10:00am PDT, 1:00pm EDT The global pandemic has increased focus and scrutiny on molecular diagnostic assay development, resulting in a need for assays that provid...
NOV 09, 2022 8:00 AM PST
C.E. CREDITS
NOV 09, 2022 8:00 AM PST
Date: November 09, 2022 Time: 8:00am (PST), 11:00am (EST), 5:00pm (CET) The field of cell and gene therapy is rapidly growing. In particular, the use of lentiviruses in CAR-T applications is...
Loading Comments...
Show Resources